Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133113) titled 'Medium-term Effects of Treatments in Autoimmune Encephalitis' on Aug. 13.
Study Type: Observational
Primary Sponsor: Hospices Civils de Lyon
Condition:
NMDAR Autoimmune Encephalitis
LGI1 Antibody Associated Encephalitis
CASPR2-Antibody
IgLON5
GAD65
GFAP
Intervention:
Other: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
Recruitment Status: Recruiting
Date of First Enrollment: September 1, 2024
Target Sample Size: 200
Countries of Recruitment:
France
To know more, vis...